Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3041-3052

  Wang, Chang Yi ^a   Finstad, Connie L ^a   Walfield, Alan M ^a   Sia, Charles ^a   Sokoll, Kenneth K ^a   Chang, Tseng Yuan ^a   Fang, Xin De ^a   Hung, Chung Ho ^a   Hutter Paier, Birgit ^b   Windisch, Manfred ^b  

^a United Biomedical Inc   (United States)

^b JSW Life Sciences GmbH   (Austria)

Author keywords

Alzheimer disease immunotherapy; APP transgenic mice; A vaccine; Non human primate toxicology

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIGEN; PLACEBO; UBITH; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; BABOON; CENTRAL NERVOUS SYSTEM; CIRCULATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACACA; MALE; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TOXICITY TESTING;

EID: 33947582998     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.031     Document Type: Article

References (29)

1. Hardy J., and Selkoe D.J. The Amyloid Hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
2. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 6815 (2000) 979-982
3. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 6815 (2000) 982-985
4. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
5. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100 4 (2003) 2023-2028
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 8 (2000) 916-919
7. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 15 (2001) 8850-8855
8. Morgan D., and Gitter B.D. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol Aging 25 5 (2004) 605-608
9. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 9 (2005) 1553-1562
10. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 4 (2003) 547-554
11. Greenberg S.M., Bacskai B.J., and Hyman B.T. Alzheimer disease's double-edged vaccine. Nat Med 9 4 (2003) 389-390
12. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
13. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 1 (2004) 11-20
14. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 4 (2003) 448-452
15. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 11 (2002) 1263-1269
16. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112 3 (2003) 415-422
17. Rockenstein E., Mallory M., Mante M., Sisk A., and Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta (1-42). J Neurosci Res 66 4 (2001) 573-582
18. Rockenstein E.M., McConlogue L., Tan H., Power M., Masliah E., and Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 270 47 (1995) 28257-28267
19. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94 8 (1997) 4109-4112
20. Wang C.Y. Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease. United States patent application publication no. US 2004/0247612 A1 (2004), United Biomedical Inc., United States
21. Wang C.Y. Artificial T helper epitopes as immune stimulators for synthetic peptide immunogens. US patent no. 6,713,301 B1 (2004), United Biomedical Inc., United States
22. Wang C.Y., Chang T.Y., Walfield A.M., Ye J., Shen M., Chen S.P., et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20 19-20 (2002) 2603-2610
23. Wang C.Y., Shen M., Tam G., Fang X.D., Ye J., Shen F., et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 21 1-2 (2002) 89-97
24. Wang C.Y., and Walfield A.M. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 23 17-18 (2005) 2049-2056
25. Wang C.Y., Walfield A.M., Fang X., Hammerberg B., Ye J., Li M.L., et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 21 15 (2003) 1580-1590
26. Sigurdsson E.M., Wisniewski T., and Frangione B. A safer vaccine for Alzheimer's disease?. Neurobiol Aging 23 6 (2002) 1001-1008
27. McCluskie M.J., and Davis H.L. CpG DNA as mucosal adjuvant. Vaccine 18 3-4 (1999) 231-237
28. Sokoll K.K. Stabilized synthetic immunogen delivery system. US patent application publication no. US 2004/0009897 Al (2004), United Biomedical Inc., United States
29. Verdier F., Burnett R., Michelet-Habchi C., Moretto P., Fievet-Groyne F., and Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23 11 (2005) 1359-1367